22 April 2021
: Case report 
Breakthrough Bleeding Episodes at Minimum and Improvement in Quality of Life in a Child with Severe Hemophilia A with Inhibitors Treated with Emicizumab: A Case Report from Chile
Rare disease
Viviana Abarca-Villaseca1ABCDEF*, Verónica Soto-Arellano2ABCDEFDOI: 10.12659/AJCR.929598
Am J Case Rep 2021; 22:e929598
Table 2. Direct costs.
| Costs (USD) | 1 year before emicizumab | 1 year after emicizumab | Variation |
|---|---|---|---|
| Exams | 1,512 | 77 | −94.9% |
| Medical fees | 1,300 | 66 | −94.9% |
| Hospitalizations | 632 | 0 | −100.0% |
| Medications | 683,832 | 206,279 | −69.8% |
| Travels | 854 | 607 | −29.1% |
| Job opportunity cost | 11,839 | 0 | −100.0% |
| Total | 699,969 | 207,028 | −70.4% |
| Medication cost as percentage of total cost | 97.7% | 99.6% |